Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
- Journal:
- Journal of Clinical Oncology
- Published:
- DOI:
- 10.1200/jco-25-00640
- Affiliations:
- 3
- Authors:
- 29
| Institutions | Authors | Share |
|---|---|---|
| The University of Texas MD Anderson Cancer Center, United States of America (USA) | 0.97 | |
| Montefiore Medical Center, Einstein, United States of America (USA) | 0.03 |